Clinical trial
The Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists Cost of Care Study: a German Claims Data Analysis
NCT04295005 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists Cost of Care Study: a German Claims Data Analysis
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Observational
- Overall status
- Completed
- Start date
- November 16, 2020
- Completion date
- September 30, 2021
- Enrollment
- 24,500 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.